Stock Monitor: Illumina Post Earnings Reporting

LONDON, UK / ACCESSWIRE / April 26, 2018 / Active-Investors.com has just released a free research report on Intec Pharma Ltd (NASDAQ: NTEC). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=NTEC as the Company's latest news hit the wire. On April 24, 2018, the Company, which is a clinical-stage biopharmaceutical organization focused on developing drugs based on its proprietary Accordion Pill platform technology, declared that it presented data from two Phase-1 studies of its proprietary Accordion Pill Carbidopa/Levodopa (AP-CD/LD) for Parkinson's disease at the American Academy of Neurology 2018 Annual Meeting (AAN 2018), in Los Angeles. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Illumina, Inc. (NASDAQ: ILMN), which also belongs to the Healthcare sector as the Company Intec Pharma. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=ILMN

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Intec Pharma most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=NTEC

R. Michael Gendreau, M.D., Ph.D., Chief Medical Officer of Intec Pharma, showcased the poster presentation titled ?Optimizing Delivery of Carbidopa/Levodopa via the Accordion Pill: Comparative PK and Safety From 2 Randomized Crossover Studies in Healthy Volunteers' at the AAN 2018 on April 23, 2018. The poster presentation received considerable interest from the neurologists attending the meeting. This would help in completing the enrollment for the Company's Phase-3 study and also enhance awareness of its AP-CD/LD program.

About Accordion Pill Technology

Intec Pharma's Accordion Pill is an oral drug delivery system, specifically designed to enhance the efficacy and safety of existing and under-development drugs by leveraging the efficient gastric retention and specific release mechanism. AP-CD/LD is Intec Pharma's product candidate that is being developed for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients. At present, the product is in its clinical trial stage.

About the Phase-1 Studies

The Phase-1 studies assessed the pharmacokinetics (PK) and safety of AP-CD/LD in comparison to immediate-release (IR) CD/LD (Sinemet), under various meal conditions in healthy adults.

  • The IN 11 005 was a randomized, two?way crossover study, wherein healthy adults were administered a single dose of AP-CD/LD 50mg/500mg and two consecutive doses of IR-CD/LD 25mg/250mg (0 h and 4 h) after an overnight fast, with a 7-day washout between treatments.
  • The IN 14 001 was a randomized, three-way crossover food-effect PK study, wherein healthy adults were administered a single dose of AP-CD/LD 50mg/500mg, after high-calorie, low/medium calorie, or fasting conditions.
  • Intec Pharma enrolled 18 healthy volunteers in the IN 11 005 study and 30 healthy volunteers in the IN 14 001 study.

Results from the Phase-1 Studies

IN 11 005 Study - In the IN 11 005 study, AP-CD/LD demonstrated more consistent mean LD plasma concentrations overtime, with reduced peak-trough differences versus IR-CD/LD. However, the mean plasma concentration of CD was similar between IR-CD/LD and AP-CD/LD. Apparent half-life (t1/2) was increased from 1.8 hours with IR-CD/LD to 5.2 hours with AP-CD/LD, and Cmax was decreased from 4,062 ng/mL to 1,951 ng/mL.

IN 14 001 Study - In the IN 14 001 study, LD plasma Cmax concentrations were similar, after either a low/medium calorie or high-calorie meal. However, more variability was noted under fasting conditions, including considerably shorter retention time versus either fed condition. Moreover, mean CD plasma Cmax concentrations were comparable between the low/medium and high-calorie meals, but higher at majority of the collection times with fasting.

Dr. Gendreau believes that this positive data shows that Intec Pharma's technology provided more consistent LD plasma levels and less peak?trough fluctuation compared to IR?CD/LD. This finding indicates that AP-CD/LD should be taken with meals, which is in-line with the current dosing regimen in the Company's ongoing Phase-3 clinical trial of AP-CD/LD to treat advanced Parkinson's disease patients.

Stock Performance Snapshot

April 25, 2018 - At Wednesday's closing bell, Intec Pharma's stock rose 2.94%, ending the trading session at $5.25.

Volume traded for the day: 214.47 thousand shares, which was above the 3-month average volume of 202.25 thousand shares.

Stock performance for year-to-date - up 1.94%

After yesterday's close, Intec Pharma's market cap was at $136.86 million.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 0.1% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors